Wangying

Associate Professor, Master's Supervisor in Marine Pharmacy. Wang Ying obtained a doctoral degree in Microbiology and Biopharmaceuticals from China Pharmaceutical University and dedicated to exploring the functions and mechanisms of non coding RNA and its derived novel micropeptides in the occurrence and development of diseases, discovering endogenous micropeptides, and modifying and optimizing them to develop First-In-Class peptide drugs, providing new drug strategies for the diagnosis and treatment of these diseases. Wang Ying engaged in long-term preclinical research and development of peptide drugs for anti-tumor and anti rheumatoid arthritis, and obtained 2 clinical approvals for new drugs. Wang Ying has published multiple papers in journals such as Signal Transduct Target Ther (IF: 38.104), J Am Chem Soc (IF: 16.383), Acta Pharm Sin B (14.903), Mol Ther Nucleic Acids (IF: 0.183), Cell Death Dis (IF: 9.685), and Oncogene (IF: 8.756), with a cumulative impact factor of over 100 as the first author. Wang Ying applied for two Chinese invention patents and was granted one patent. She won the second prize of China Industry University Research Cooperation Innovation Achievement Award and the second prize of the 6th Jiangsu Pharmaceutical Science and Technology Progress Award.

1）Wang Y^#, Li M^#, Xu H*, et al. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes, Signal Transduct Target Ther, 2021, 6(1): 409. (IF=38.104)

2）Wang Y^#, Lu J^#, Xu H*, et al. Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC, Molecular Therapy - Nucleic Acids, 2020, 20: 421-437. (IF=10.183)

3）Wang Y^#, Li D^#, Xu H*, et al. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma, Cell Death and Disease, 2020, 11(8): 664. (IF=9.685)

4）Yang P^#, Wang Y^#, Xu H*, et al. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide, Journal of the American Chemical Society. 2020, 142(44): 18874-18885. (IF=16.383)

5）Li M^#, Wang Y^#, Xu H*, et al. Integrins as attractive targets for cancer therapeutics, Acta Pharmaceutica Sinica B, 2021, 11(9): 2726-2737. (IF=14.903)

6）Lin C^#, Wang Y^#, Guo C, Xu H*, et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells, Oncogene, 2017, 36(38): 5392-5406. (IF=8.756)

7）Li D^#, Wang Y^#, Xu H*, Hu J*, et al. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice, Journal of Neuroinflammation, 2020, 17(1): 126. (IF=9.587)

Li D^#, Wang Y^#, Xu H*, Hu J*, et al. CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages, International Immunopharmacology, 2020, 78: 106046. (IF=5.714)

Mechanism Study of Non-coding RNA and Micropeptides in Diseases